Business Context and Reporting Period
Company: Altimmune, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 24, 2018
Event: Entry into a Material Definitive Agreement for a private placement of common stock.
Key Financial Metrics
This filing reports on a specific capital raise transaction rather than periodic operating results. Key transaction metrics include:
- Shares Issued: 286,633 shares of common stock.
- Offering Price: $17.02 per share.
- Gross Proceeds: Approximately $4.88 million (calculated as 286,633 shares x $17.02).
- Net Proceeds: Approximately $4.5 million (after deducting placement agent fees).
- Placement Agent Fee: 7.0% of gross proceeds.
- Expense Reimbursement: Up to $125,000 for the placement agent.
- Expected Closing Date: On or about September 26, 2018.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transaction-specific report.
Material Changes
The filing does not report material changes to prior period financial performance. The primary change is the execution of a Securities Purchase Agreement to raise capital, which will increase the company's cash position upon closing.
Guidance, Outlook, and Risks
Management Commentary: The offering is being made pursuant to an existing shelf registration statement on Form S-3 (File No. 333-217034). Roth Capital Partners, LLC acted as the placement agent.
Risks and Contingencies:
- The transaction is subject to the satisfaction of customary closing conditions.
- The filing explicitly states that representations, warranties, and covenants in the Purchase Agreement are for risk allocation between parties and should not be relied upon as statements of fact regarding the Company's actual condition.
- Information regarding the subject matter of representations may change after the agreement date.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected September 26, 2018).
- Confirm the final net proceeds after all transaction expenses are deducted.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants.
- Check subsequent filings for the impact of this capital raise on the company's cash runway and dilution.